Related Experiment Videos

Influence of blood pressure reduction on composite cardiovascular endpoints in clinical trials

Paolo Verdecchia1, Giorgio Gentile, Fabio Angeli

  • 1Department of Cardiology, Hospital 'Santa Maria della Misericordia', Perugia, Italy. verdec@tin.it

Journal of Hypertension
|April 9, 2010
PubMed

Insights

Lowering blood pressure (BP) significantly reduces the risk of major cardiovascular events in clinical trials. A difference of 4.6 mmHg systolic or 2.2 mmHg diastolic BP reduction is needed to show a significant impact on composite cardiovascular endpoints (CCEP).

Area of Science:

  • Cardiovascular Medicine
  • Clinical Trials Methodology
  • Hypertension Research

Background:

  • Composite cardiovascular endpoints (CCEP) are widely used in clinical trials.
  • The precise relationship between blood pressure (BP) reduction and CCEP risk is not well-established.

Purpose of the Study:

  • To meta-analyze the association between BP reduction and CCEP risk across multiple clinical trials.
  • To quantify the BP reduction necessary to achieve a statistically significant decrease in CCEP.

Main Methods:

  • Conducted a meta-analysis of 30 trials involving 221,024 patients comparing BP-lowering agents to placebo or active treatments.
  • Utilized triple (myocardial infarction, stroke, cardiovascular death) or quadruple (including congestive heart failure) CCEP as the primary outcome measure.
  • Employed multivariable meta-regression to analyze the impact of systolic BP (SBP) and diastolic BP (DBP) reduction on CCEP risk.

Main Results:

  • BP-lowering treatments reduced CCEP risk by 9% overall (P < 0.0001).
  • Each 5-mmHg reduction in SBP was associated with a 13% decreased CCEP risk (P = 0.001).
  • Each 2-mmHg reduction in DBP was associated with a 12% decreased CCEP risk (P = 0.001).
  • A minimum SBP reduction of 4.6 mmHg or DBP reduction of 2.2 mmHg was required for a 95% prediction interval below unity.

Conclusions:

  • Blood pressure reduction is a critical factor in mitigating CCEP risk in clinical trial settings.
  • A difference of at least 4.6 mmHg in SBP or 2.2 mmHg in DBP between treatment groups is likely needed to demonstrate a significant reduction in CCEP.
Abstract

Related Concept Videos

Measurement of Blood Pressure01:17

Measurement of Blood Pressure

Assessing blood pressure is a standard procedure executed in virtually all medical environments. The method utilized today was established over a hundred years ago by an innovative Russian doctor, Dr. Nikolai Korotkoff. The soft ticking noise, known as Korotkoff sounds, heard while taking blood pressure readings results from turbulent blood flow within the vessels. The apparatus required for this procedure includes a sphygmomanometer, a blood pressure cuff attached to a gauge, and a stethoscope.
Factors affecting Blood pressure01:28

Factors affecting Blood pressure

Several physiological and lifestyle factors influence blood pressure (BP). Understanding these factors is crucial as they are significant in patient education and blood pressure management.
Physiological Factors:
Hypertension and Regulation of Blood Pressure01:18

Hypertension and Regulation of Blood Pressure

Hypertension, the most common cardiovascular disease, is diagnosed through repeated measurements of elevated blood pressure. Its risks, including damage to the kidney, heart, and brain, are directly proportional to blood pressure levels. Starting from 115/75 mm Hg, the risk of cardiovascular disease doubles with each increment of 20/10 mm Hg. The diagnosis relies on blood pressure measurements, not on patient symptoms, as hypertension is often asymptomatic until end-organ damage is imminent or...
Hypertension III: Clinical Manifestations and Diagnostic Studies01:30

Hypertension III: Clinical Manifestations and Diagnostic Studies

Hypertension is asymptomatic and also referred to as the "silent killer" until it progresses to a severe stage or causes target organ disease. Patients may experience symptoms stemming from the strain on blood vessels and tissues in various organs or the heart's increased workload.Physical exams might show no abnormalities other than high blood pressure. Signs of vascular damage, when present, correspond to the organs supplied by the affected vessels, leading to target organ damage. For...
Errors occurring during blood pressure monitoring01:25

Errors occurring during blood pressure monitoring

Blood pressure monitoring is a crucial clinical procedure in diagnosing and managing various cardiovascular conditions. Despite its significance, the accuracy of blood pressure measurements can be compromised by multiple factors, potentially leading to either falsely high or low readings. These inaccuracies are critical as they can significantly impact patient care. So, it is vital to understand these challenges deeply and adopt strategic approaches to minimize errors.
Several factors...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...